Pro re nata medication for psychoses: An audit of practice in two metropolitan hospitals

Australian and New Zealand Journal of Psychiatry

Volumn 36, Issue 5, 2002, Pages 649-656

  Geffen, Josh ^a   Sorensen, Lene ^a   Stokes, Julie ^a   Cameron, Allison ^a   Roberts, Michael S ^a   Geffen, Laurence ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Audit; Medication; Practice; Pro re nata; Psychosis

Indexed keywords

ANXIOLYTIC AGENT; BENZATROPINE; BENZODIAZEPINE; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLOZAPINE; DIAZEPAM; DROPERIDOL; FLUPENTIXOL; HALOPERIDOL; LITHIUM; MIDAZOLAM; NEUROLEPTIC AGENT; OLANZAPINE; OXAZEPAM; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; TRIHEXYPHENIDYL; VALPROIC ACID; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG INDICATION; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITAL ADMISSION; HOSPITAL CARE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; MEDICAL AUDIT; MEDICAL DOCUMENTATION; MEDICAL RECORD; MORBIDITY; PATIENT COMPLIANCE; PRESCRIPTION; PREVALENCE; PSYCHOSIS; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MEDICAL AUDIT; MIDDLE AGED; PATIENT ADMISSION; RETROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 0036796297     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.2002.01069.x     Document Type: Article

References (34)

1. Jablensky A, McGrath J, Hermann H et al. People living with psychotic illness: an Australian study 1997-98. Report 4. National Survey of Mental Health and Wellbeing. Canberra: Commonwealth Department of Health and Aged Care, 1999.
2. Mason A, De Wolfe A. Use of drugs in a mental hospital: as needed (PRN) antipsychotic medications. Current Therapeutic Research 1974; 16:853-860.
3. Fishel A, Ferreiro B, Rynerson M, Nickel M, Jackson B, Hannah B. As needed psychotropic medications: prevalence indications and results. Journal of Psychosocial Nursing 1994; 32:27-32.
4. McLaren S, Browne F, Taylor P. A study of psychotropic medication given 'as required' in a secure regional unit. British Journal of Psychiatry 1990; 156:732-735.
5. Walker R. PRN psychotropic drug use on a psychiatric unit. Psychiatric Quarterly 1991; 62:1-8.
6. Craig J, Thomas J, Bracken J. An epidemiological study of prn/stat medication use in a state psychiatric hospital. Annals of Clinical Psychiatry 1995; 7:57-64.
7. Craven J, Voore P, Voineskos G. PRN medication in psychiatric inpatients. Canadian Journal of Psychiatry 1987; 32:199-203.
8. Parker G, Lambert T, McGrath J, McGorry P, Tiller J. Neuroleptic management of schizophrenia: a survey and commentary on Australian psychiatric practice. Australia and New Zealand Journal of Psychiatry 1998; 32:50-58.
9. Miller C, Mohr F, Umbricht D. The prevalence of acute extrapyramidal symptoms in patients treated with clozapine, risperidone and conventional antipsychotics. Journal of Clinical Psychiatry 1998; 59:69-75.
10. Collaborative Working Group on Clinical Trial Evaluations. Assesssment of EPS and tardive dyskinesia in clinical trials. Journal of Clinical Psychiatry 1998; 59 (Suppl. 12):23-27.
11. Collaborative Working Group on Clinical Trial Evaluations. Assessing the effects of atypical antipsychotics on negative symptoms. Journal of Clinical Psychiatry 1998; 59 (Suppl. 12):28-34.
12. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Archives of General Psychiatry 1974; 31:67-72.
13. Fleischacker W, Meise U, Gunter V. Compliance with antipsychotic drug treatment: Influence of side effects. Acta Psychiatrica Scandinavica 1994; 382 (Suppl.): 11-15.
14. Marder S. Antipsychotic drugs and relapse prevention. Schizophrenia Research 1999; 35:S87-S92.
15. Desai N, Huq Z, Martin S, McDonald G. Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. Advances in Therapy 1999; 16:78-87.
16. Dubin W, Weiss K, Dorn J. Pharmacotherapy of psychiatric emergencies. Journal of Clinical Psychopharmacology 1986; 6:210-222.
17. Dubin W. Rapid tranquillisation: antipsychotics or benzodiazepines. Journal of Clinical Psychiatry 1988; 49 (Suppl.):5-10.
18. Garza-Trevino E, Hollister L, Overall J, Alexander W. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry 1989; 146:1599-1601.
19. Battaglia J, Moss S, Rush J et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double blind emergency department study. American Journal of Emergency Medicine 1997; 15:335-340.
20. Salzman C, Solomon D, Miyawaki E, Glassman R, Rood L, Flowers E. Parenteral lorazepam vs parenteral haloperidol for the control of psychotic disruptive behaviour. Journal of Clinical Psychiatry 1991; 52:177-180.
21. Foster S, Kessel J, Berman M, Simpson G. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology 1997; 12:175-179.
22. Demczar D, Levin G. Use of atypical antipsychotics on an as-needed basis. Journal of Pharmacy Technology 1996; 12:145-148.
23. RANZCP Committee on Psychotropic Drugs and Other Physical Treatments. Response to 'Cardiotoxicity associated with the use of intravenous haloperidol' (letter). Australian and New Zealand Journal of Psychiatry 1999; 33:943-944.
24. Gray R, Smedley N, Thomas B. Focus on Mental Health Nursing. Administration of PRN medication by mental health nurses. British Journal of Nursing 1996; 5:1317-1322.
25. McKenzie A, Kudinoff T, Benson A, Archillingham A. Administration of PRN medication: a descriptive study of nursing practice. Australia and New Zealand Journal of Mental Health Nursing 1999; 8:187-191.
26. Bazire S. Drug treatment options in psychiatric illness. In: Bazire S. Psychotropic Drug Directory 1999. Salisbury: Mark Allen Publishing, 1999; 1-115.
27. Mould D, DeFeo T, Reele S, Millac G, Patel H. Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepam. Clinical Pharmacology and Therapeutics 1995; 58:35-43.
28. Lambert T. Utilily for neuroleptic dose conversion. (CD-ROM). Melbourne: Multimedia in Psychiatry Unit. University of Melbourne, 1998.
29. Siegfried N. A review of comorbidity: major mental illness and problematic substance abuse. Australian and New Zealand Journal of Psychiatry 1998; 32:707-717.
30. Whitworth A, Fleischacker W. Adverse effects of antipsychotic drugs. International Clinical Psychopharmacology 1995; 9 (Suppl. 5):21-27.
31. Milling R, Faulkner L, Craig J. Problems in the recognition and treatment of patients with dual diagnosis. Journal of Substance Abuse Treatment 1994; 11:267-271.
32. Geffen J, Cameron A, Sorensen L, Stokes J, Roberts MS, Geffen L. PRN medication for psychoses: the knowledge and beliefs of mental health doctors and nurses. Australian and New Zealand Journal of Psychiatry 2002; 36:642-648.
33. Kane J, McGlashan T. Treatment of schizophrenia. Lancet 1995; 346:820-825.
34. Wolkowitz O, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. American Journal of Psychiatry 1991; 148:714-726.